Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2452406 | 0.97 | THRB (0.30) | THRBMEN1KMT2A | |
| SCHEMBL5598538 | 0.86 | — | — | |
| SCHEMBL22212972 | 0.86 | — | — | |
| SCHEMBL23601719 | 0.83 | THRB (0.39) | THRBMEN1KMT2A | |
| SCHEMBL24587061 | 0.82 | MEN1 (0.43) | THRBMEN1KMT2A | |
| SCHEMBL24587092 | 0.82 | MEN1 (0.43) | THRBMEN1KMT2A | |
| SCHEMBL11687131 | 0.81 | — | — | |
| SCHEMBL13421612 | 0.79 | THRB (0.32) | THRBMEN1KMT2A | |
| SCHEMBL8172994 | 0.78 | THRB (0.35) | THRBMEN1KMT2A | |
| SCHEMBL22570751 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1581476-B1 | AMIDES AS 11-BETA HYDROXYSTEROID DEHYDROGENASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2016-11-16 | — | — | EP | disclosed |
| EP-2859030-A2 | LOW-VISCOSITY PHENOLIC DIGLYCIDYL ETHERS FOR EPOXY COATING APPLICATIONS | Dow Global Technologies LLC (US) | 2015-04-15 | — | — | EP | disclosed |
| US-8710077-B2 | Cycloalkylamine substituted isoquinoline and isoquinolinone derivatives | SANOFI (FR) | 2014-04-29 | — | — | US | disclosed |
| WO-2013188255-A2 | LOW-VISCOSITY PHENOLIC DIGLYCIDYL ETHERS FOR EPOXY COATING APPLICATIONS | DOW GLOBAL TECHNOLOGIES LLC (US) | 2013-12-19 | — | — | WO | disclosed |
| US-7968601-B2 | Treating excess cortisol formation; obesity, cardiovascular disorders, glaucoma, osteoporosis, Alzheimer's Disease; antidiabetic agents | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-06-28 | — | — | US | disclosed |
| US-7968601-B2 | Treating excess cortisol formation; obesity, cardiovascular disorders, glaucoma, osteoporosis, Alzheimer's Disease; antidiabetic agents | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-06-28 | — | — | US | disclosed |
| US-20100056553-A1 | Cycloalkylamine substituted isoquinoline and isoquinolinone derivatives | SANOFI-AVENTIS (FR) | 2010-03-04 | — | — | US | disclosed |
| US-20080096869-A1 | ADAMANTYL ACETAMIDES AS 11-BETA HYDROXYSTEROID DEHYDROGENASE INHIBITORS | LINDERS JOANNES T M | 2008-04-24 | — | — | US | disclosed |
| US-20080096869-A1 | ADAMANTYL ACETAMIDES AS 11-BETA HYDROXYSTEROID DEHYDROGENASE INHIBITORS | LINDERS JOANNES T M | 2008-04-24 | — | — | US | disclosed |
| US-7332524-B2 | Adamantyl acetamides as 11-beta hydroxysteroid dehydrogenase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-02-19 | — | — | US | disclosed |
| US-7332524-B2 | Adamantyl acetamides as 11-beta hydroxysteroid dehydrogenase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-02-19 | — | — | US | disclosed |
| US-20070135641-A1 | Synthesis | PALMER RICHARD M J | 2007-06-14 | — | — | US | disclosed |
| US-7189852-B2 | Preparing renzapride (hydrochloride) on a laboratory or industrial scale by a simplified process of forming the acyl chloride derivative of 2-(methoxy),3-acyamino,5-chlorobenzoic acid by reacting oxalyl or thionyl chloride in a solvent, e.g. dimethylformamide; coupling with 1-diazabicylo(3.3.1)nonane | ALIZYME THERAPEUTICS LIMITED (GB) | 2007-03-13 | — | — | US | disclosed |
| WO-2004056744-A1 | ADAMANTYL ACETAMIDES AS HYDROXYSTEROID DEHYDROGENASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096869-A1 | ADAMANTYL ACETAMIDES AS 11-BETA HYDROXYSTEROID DEHYDROGENASE INHIBITORS | DHCR7, HSD3B2, HSD3B1 | THRB 1864/4885MEN1 2380/4885KMT2A 3938/4885 |
| US-20070135641-A1 | Synthesis | ALKBH5, AZI2, ALKBH1 | THRB 3529/4885MEN1 2023/4885KMT2A 121/4885 |
| US-20100056553-A1 | Cycloalkylamine substituted isoquinoline and isoquinolinone derivatives | MYLK2, MYLK, MYLK3 | THRB 3114/4885MEN1 4289/4885KMT2A 2511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.